# A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.

> **NCT07557004** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Nanjing Sanhome Pharmaceutical, Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- HR+ / HER2- Advanced Breast Cancer

## Interventions

- **DRUG:** SH3765+Fulvestrant

## Key facts

- **NCT ID:** NCT07557004
- **Lead sponsor:** Nanjing Sanhome Pharmaceutical, Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07557004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07557004, "A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07557004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*